Hightech Medical Services S.R.L.
- Address
- lock Available on a paid plan
Hightech Medical Services S.R.L. - Advanced Metabolic and Hepatic Disease Research
Hightech Medical Services S.R.L. is a specialized clinical research center with demonstrated expertise in conducting complex metabolic, hepatic, and cardiovascular disease trials. The center has established itself as a key contributor to advancing therapeutic solutions for conditions involving liver disease, metabolic dysfunction, and cardiovascular risk, with particular emphasis on multi-phase, placebo-controlled studies requiring sophisticated patient management and histological assessment capabilities.
- Non-alcoholic steatohepatitis (NASH) and liver fibrosis treatment studies, including novel therapeutic agents and histological improvement endpoints
- Primary biliary cholangitis (PBC) research, encompassing both short-term efficacy trials and long-term clinical outcome studies in cirrhotic populations
- Cardiovascular disease prevention and obesity-related complications, including innovative studies targeting lipoprotein(a) reduction and cardiorenal outcomes
- Gastrointestinal and autoimmune disorders, including celiac disease research focused on symptom improvement and mucosal healing
The center demonstrates proficiency in managing trials with complex inclusion criteria and specialized endpoints, including liver histology assessments, biomarker normalization studies, and cardiovascular outcome trials. With experience across Phase 2 and Phase 3 protocols, Hightech Medical Services supports investigations ranging from proof-of-concept efficacy studies to large-scale, event-driven trials designed to evaluate clinical outcomes and prevent disease progression in high-risk populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Amgen Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.3trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hightech Medical Services S.R.L.
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus | Alumis Inc. | Phase II | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2023-08-02 | 2023-08-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.